Literature DB >> 29173272

Case: Bacillus Calmette-Guerin (BCG)-induced Reiter syndrome with an attempt at repeat BCG induction.

Douglas C Cheung1, Alexandra L Millman1, Robert J Hamilton1.   

Abstract

Entities:  

Year:  2017        PMID： 29173272      PMCID： PMC5783707          DOI： 10.5489/cuaj.4759

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  15 in total

Review 1.  Preventing progression and improving survival with BCG maintenance.

Authors:  D L Lamm
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

Review 2.  The ever-expanding association between rheumatologic diseases and tuberculosis.

Authors:  Carlos Franco-Paredes; Alejandro Díaz-Borjon; Mark A Senger; Lorena Barragan; Michael Leonard
Journal:  Am J Med       Date:  2006-06       Impact factor: 4.965

Review 3.  BCG immunotherapy--from pathophysiology to clinical practice.

Authors:  Moshe Tishler; Yehuda Shoenfeld
Journal:  Expert Opin Drug Saf       Date:  2006-03       Impact factor: 4.250

4.  Frequency of reactive arthritis, uveitis, and conjunctivitis in Japanese patients with bladder cancer following intravesical BCG therapy: A 20-year, two-centre retrospective study.

Authors:  Yoshinori Taniguchi; Hirofumi Nishikawa; Takashi Karashima; Yasuhiko Yoshinaga; Shimpei Fujimoto; Yoshio Terada
Journal:  Joint Bone Spine       Date:  2016-11-04       Impact factor: 4.929

Review 5.  Effective dose and adverse effects of maintenance Bacillus Calmette-Gue'Rin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial.

Authors:  Ari Astram; Adianti Khadijah; Prahara Yuri; Ahmad Zulfan; Chaidir A Mochtar; R Danarto; Rainy Umbas; Agus Rizal A H Hamid
Journal:  Acta Med Indones       Date:  2014-10

6.  A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.

Authors:  Antonio Ojea; José Luís Nogueira; Eduardo Solsona; Nicolás Flores; Jesús María Fernández Gómez; Jesús Rodríguez Molina; Venancio Chantada; José Emilio Camacho; Luís Martínez Piñeiro; Rafael Hernandez Rodríguez; Santiago Isorna; Miguel Blas; José A Martínez-Piñeiro; Rosario Madero
Journal:  Eur Urol       Date:  2007-04-27       Impact factor: 20.096

7.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

Review 8.  Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature.

Authors:  Luigi Bernini; Carlo Umberto Manzini; Dilia Giuggioli; Marco Sebastiani; Clodoveo Ferri
Journal:  Autoimmun Rev       Date:  2013-06-29       Impact factor: 9.754

Review 9.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

Review 10.  Immunotherapy for bladder cancer.

Authors:  Oliver Fuge; Nikhil Vasdev; Paula Allchorne; James Sa Green
Journal:  Res Rep Urol       Date:  2015-05-04
View more
  3 in total

Review 1.  Reactive Arthritis following Bacillus Calmette-Guerin Therapy for Bladder Cancer: a Systematic Literature Review.

Authors:  Kawther Ben Abdelghani; Lilia Nacef; Saoussen Miladi; Meriem Sellami; Kmar Ouenniche; Leila Souabni; Selma Kassab; Selma Chekili; Alia Fazaa; Ahmed Laatar
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 2.  Reactive Arthritis Update: Spotlight on New and Rare Infectious Agents Implicated as Pathogens.

Authors:  Henning Zeidler; Alan P Hudson
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

3.  Effectiveness of Steroid Pulse Therapy for Systemic Side Effects after Bacillus Calmette-Guérin Intravesical Instillation Therapy: A Series of Five Cases.

Authors:  Tatsuya Umemoto; Jun Naruse; Yukio Usui; Hidenori Zakoji; Hideshi Miyakita; Akira Miyajima
Journal:  Case Rep Urol       Date:  2021-07-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.